CRISPR Therapeutics AG
更新済

Crispr consolidates, higher lows but with upward resistance

111
I stopped out on Crispr at 173.50 and since then the stock has consolidated setting higher lows while unable to break through resistance at around 173-173.50. This has had a significant impact on ARK-G which fed off the strong up-moves Crispr has made over the last six months.

It is believed that Crispr is the Apple of the future. Many times over Apple's price moves in the last decade, there were months and even years with little to no upward movement. For many, the buy and hold strategy may be the best approach.
ノート
Still working neatly within the wedge. Time to plan for re-entry.

スナップショット

免責事項

これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。